- Unlearn develops innovative AI-driven platforms to enhance the efficiency of clinical trials through predictive simulations and digital twins.
- The company uses machine learning models to create "digital twins" of patients, significantly reducing the size and duration of clinical trials.
- With a focus on improving patient outcomes and accelerating drug development, Unlearn aims to transform the way the pharmaceutical industry conducts clinical research.
Clinical trials have remained crucial in healthcare and pharmaceutical industries to ensure the safety and efficacy of new treatments. However, these trials can be long processes with high costs and more sophisticated labour challenges.
These processes can also be time-consuming and can delay their availability to patients.
In this milieu, Unlearn strives to advance artificial intelligence to eliminate trial and error in medicine by enabling quick and confident clinical trials.
Pioneering AI-Driven Clinical Trials
Unlearn is a cutting-edge technology company that seeks to revolutionize the clinical trial process by leveraging the power of artificial intelligence.
Founded by Charles Fisher, Aaron Smith and Jonathan Walsh, this US-based company is built on a mission to advance artificial intelligence to eliminate trial and error in medicine.
The products help biopharma companies develop drugs more ethically and efficiently by leveraging generative machine learning models to reduce the number of patients required for placebo controls in clinical trials.
They enable clinical trial sponsors to run RCTs, require fewer participants, produce better evidence about therapeutic efficacy, and which fewer participants who need to be given placebos.
Digital Twins: A Game-Changing Approach to Clinical Trials
At the core of Unlearn is the most innovative product that can generate digital twins.
Their AI-based platform, built on advanced machine learning algorithms, enables the creation of "digital twins"—virtual replicas of real patients.
The platform manipulates existing data from previous clinical trials and studies, applies machine learning techniques, and simulates a patient's response to a treatment.
This enables researchers to model potential outcomes for real patients without enrolling a large number of participants, making the clinical trial process more dexterous and cost-effective.
AI-Driven Clinical Trials and its Success
AI is an integral part of the clinical trials they undertake thus enhancing patient outcomes.
The common dilemma with traditional trials is their extremely long duration before any outcomes can be drawn, the process can be rendered useless and inefficient.
With the ability to expedite clinical trials, the platform can help patients benefit from innovative treatments sooner. This makes drug development more efficient and accessible.
By also reducing the time and cost associated with new drug development to a significant extent, Unlearn also helps pharmaceutical companies in the process whilst ensuring rigorous testing standards.
Additionally, the platform reduces the need for placebo groups in trials by enabling the use of digital twins as control groups.
This is a major step forward in patient-centered care, as fewer patients will have to receive placebo treatments, which can be ethically challenging in certain clinical scenarios.
Potential Growth and Future of Unlearn
As the healthcare industry continues to usher in more advanced technological advancements, Unlearn is at the forefront of this revolution by enabling AI to help in clinical trials.
This impactful transformation of healthcare has also brought the company to subsequent investments.
Unlearn has raised a total of $134.9 million in total funding with the most recent Series C round led by Altimeter Capital.
This funding will support the expansion of Unlearn.AI’s platform, enabling the company to scale its operations and continue developing its AI-driven solutions for the pharmaceutical industry.
Edited By Annette George
